Literature DB >> 21296504

Perceived risk associated with ecstasy use: a latent class analysis approach.

S S Martins1, R G Carlson, P K Alexandre, R S Falck.   

Abstract

This study aims to define categories of perceived health problems among ecstasy users based on observed clustering of their perceptions of ecstasy-related health problems. Data from a community sample of ecstasy users (n=402) aged 18 to 30, in Ohio, was used in this study. Data was analyzed via Latent Class Analysis (LCA) and Regression. This study identified five different subgroups of ecstasy users based on their perceptions of health problems they associated with their ecstasy use. Almost one third of the sample (28.9%) belonged to a class with "low level of perceived problems" (Class 4). About one fourth (25.6%) of the sample (Class 2), had high probabilities of "perceiving problems on sexual-related items", but generally low or moderate probabilities of perceiving problems in other areas. Roughly one-fifth of the sample (21.1%, Class 1) had moderate probabilities of perceiving ecstasy health-related problems in all areas. A small proportion of respondents (11.9%, Class 5) had high probabilities of reporting "perceived memory and cognitive problems", and of perceiving "ecstasy-related problems in all areas" (12.4%, Class 3). A large proportion of ecstasy users perceive either low or moderate risk associated with their ecstasy use. It is important to further investigate whether lower levels of risk perception are associated with persistence of ecstasy use.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296504      PMCID: PMC3049947          DOI: 10.1016/j.addbeh.2011.01.013

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  28 in total

1.  Respondent-driven sampling to recruit MDMA users: a methodological assessment.

Authors:  Jichuan Wang; Robert G Carlson; Russel S Falck; Harvey A Siegal; Ahmmed Rahman; Linna Li
Journal:  Drug Alcohol Depend       Date:  2004-12-22       Impact factor: 4.492

2.  The content of ecstasy tablets: implications for the study of their long-term effects.

Authors:  Jon C Cole; Mike Bailey; Harry R Sumnall; Graham F Wagstaff; Les A King
Journal:  Addiction       Date:  2002-12       Impact factor: 6.526

3.  From "Candy Kids" to "Chemi-Kids": a typology of young adults who attend raves in the midwestern United States.

Authors:  Jill A McCaughan; Robert G Carlson; Russel S Falck; Harvey A Siegal
Journal:  Subst Use Misuse       Date:  2005       Impact factor: 2.164

4.  Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low.

Authors:  H V Curran; R A Travill
Journal:  Addiction       Date:  1997-07       Impact factor: 6.526

Review 5.  Altered states: the clinical effects of Ecstasy.

Authors:  J C Cole; H R Sumnall
Journal:  Pharmacol Ther       Date:  2003-04       Impact factor: 12.310

6.  Modifiable risk factors of ecstasy use: risk perception, current dependence, perceived control, and depression.

Authors:  Kit Sang Leung; Arbi Ben Abdallah; Jan Copeland; Linda B Cottler
Journal:  Addict Behav       Date:  2009-10-18       Impact factor: 3.913

7.  Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP.

Authors:  Manuel Tancer; Chris-Ellyn Johanson
Journal:  Drug Alcohol Depend       Date:  2003-10-24       Impact factor: 4.492

Review 8.  Preventing problems in Ecstasy users: reduce use to reduce harm.

Authors:  Matthew J Baggott
Journal:  J Psychoactive Drugs       Date:  2002 Apr-Jun

9.  Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users.

Authors:  H J Stuerenburg; K Petersen; T Bäumer; M Rosenkranz; C Buhmann; R Thomasius
Journal:  Neuro Endocrinol Lett       Date:  2002-06       Impact factor: 0.765

Review 10.  Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate.

Authors:  Kelly M Smith; Lisa L Larive; Frank Romanelli
Journal:  Am J Health Syst Pharm       Date:  2002-06-01       Impact factor: 2.637

View more
  6 in total

1.  Cognitive performance profiles by latent classes of drug use.

Authors:  P Truman Harrell; Brent Edward E Mancha; Silvia S Martins; Pia M Mauro; Julie H Kuo; Michael Scherer; Karen I Bolla; William W Latimer
Journal:  Am J Addict       Date:  2014-03-15

2.  Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors.

Authors:  P T Harrell; B E Mancha; H Petras; R C Trenz; W W Latimer
Journal:  Drug Alcohol Depend       Date:  2011-10-24       Impact factor: 4.492

3.  A Latent Class Analysis of Risk Factors for Acquiring HIV Among Men Who Have Sex with Men: Implications for Implementing Pre-Exposure Prophylaxis Programs.

Authors:  Philip A Chan; Jennifer Rose; Justine Maher; Stacey Benben; Kristen Pfeiffer; Alexi Almonte; Joanna Poceta; Catherine E Oldenburg; Sharon Parker; Brandon Dl Marshall; Mickey Lally; Kenneth Mayer; Leandro Mena; Rupa Patel; Amy S Nunn
Journal:  AIDS Patient Care STDS       Date:  2015-09-21       Impact factor: 5.078

4.  Phylogenetic Investigation of a Statewide HIV-1 Epidemic Reveals Ongoing and Active Transmission Networks Among Men Who Have Sex With Men.

Authors:  Philip A Chan; Joseph W Hogan; Austin Huang; Allison DeLong; Marco Salemi; Kenneth H Mayer; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

5.  A latent class approach to treatment readiness corresponds to a transtheoretical ("Stages of Change") model.

Authors:  Paul Truman Harrell; R C Trenz; M Scherer; S S Martins; W W Latimer
Journal:  J Subst Abuse Treat       Date:  2013-05-22

6.  Association of contextual factors with drug use and binge drinking among White, Native American, and Mixed-Race adolescents in the general population.

Authors:  Hsing-Jung Chen; Sundari Balan; Rumi Kato Price
Journal:  J Youth Adolesc       Date:  2012-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.